Warren Alpert Foundation

The Warren Alpert Foundation operates with a clear dual mandate: advancing breakthrough medical research through institutional partnerships with elite academic medical centers, and supporting community-level educational and social services organizations in its home base of Providence, Rhode Island. Applicants must understand which track they are pursuing before approaching this foundation, as the two programs operate quite differently.

For the medical research track, the foundation has deep, longstanding relationships with Brown University (home of the Warren Alpert Medical School), Harvard Medical School, and the University of Pennsylvania — which collectively account for roughly 63% of all documented grantee dollars. First-time applicants from outside this institutional circle must demonstrate either a direct research relationship with one of these anchor institutions, or work in a disease area where the foundation has documented interest: oncology (particularly pancreatic cancer), neuroscience, immunology, HIV/virology, and most recently gene therapy.

The foundation does not rely primarily on open competitive calls. Instead, it runs targeted competitive programs — the Distinguished Scholars Fellowship (focused on a specific research area each cycle) — alongside a more open application process for general grants. For general grants above $25,000, a Letter of Inquiry is the required first step, reviewed quarterly before board meetings held in February, May, August, and November. There are no rolling deadlines; LOIs must arrive by January 10, April 10, July 10, or October 10.

The community grants track is geographically concentrated in New England, with the foundation's own language expressing preference for 'the general New England area.' Grantees like Crossroads Rhode Island, Providence Promise, Community Preparatory School, and New England food banks show consistent multi-year support patterns, suggesting the community portfolio is relationship-driven rather than competitively open. New community organizations seeking entry should align closely with the founder's philosophy: supporting young people to become economically self-sustaining contributors to society.

Executive Director August R. Schiesser leads operations; the Grant Committee is chaired by Dr. Robert H. Brown Jr. The board includes multiple physician-scientists (Dr. Fred Schiffman, Dr. Joseph Martin, Dr. Wendy Chung, Dr. Barbara McNeil), meaning proposals face scientifically literate reviewers. Generic language about 'innovative research' will not distinguish a proposal — specific disease mechanisms, measurable clinical endpoints, and translational pathways are the currency this board understands.

The Warren Alpert Foundation maintains approximately $397–420 million in assets across the FY2019–FY2024 period, with annual total giving ranging from $21.0 million (FY2019) to $27.7 million (FY2021). The most recent complete year (FY2023) shows $27.5 million in total giving and $22.9 million in grants paid — a healthy payout of roughly 5.6% of assets, above the standard 5% private foundation minimum. Giving dipped to $21.7 million in FY2020 (COVID impact) but rebounded strongly by FY2021–FY2023.

Grant size distribution is strikingly bimodal. The foundation's own data shows a median grant of $25,000 alongside an average of approximately $294,000–$376,000 (across different data cuts), with the range extending from $500 at the floor to $9.9 million at the ceiling. This gap signals that a small number of very large institutional grants dominate total dollar flow while the majority of individual transactions are modest. The $25,000 threshold is also functionally significant: grants at or below that figure bypass the LOI requirement entirely, representing a lower-friction entry path.

Brown University alone accounts for $17.8 million in documented grantee dollars — approximately 38% of the $46.4 million captured in the top-50 grantee dataset — spread across just two grants. Harvard ($6.7M, 2 grants) and UPenn ($4.7M, 2 grants) complete a top-three institutional tier that captures roughly 63% of recorded giving. The next tier runs $500K–$2M: Memorial Sloan Kettering ($1.82M), University of Michigan ($1.35M), National Academy of Sciences ($1M), Rhode Island Hospital ($817K), and Children's Hospital ($775K).

Disease area emphasis in the grantee list: oncology leads (Lustgarten Pancreatic Cancer Foundation $515K, Pancreatic Cancer Action Network $300K, Memorial Sloan Kettering $1.82M), followed by general biomedical research and education. Neuroscience and immunology are growing through the Distinguished Scholars program. Community/social services grants cluster in the $40,000–$100,000 range: food banks and elder services organizations across New England receive recurring grants of approximately $47,500–$50,000 each.

Geographically, Rhode Island (52 grants, 33%) and Massachusetts (42 grants, 27%) together represent 60% of all grant transactions. New York accounts for 12 grants (8%) and California for 7 (4%). The remaining states — Pennsylvania, Florida, Washington, Minnesota, Texas, and DC — collectively hold 40% of transaction count but include the largest individual grants (Penn at $4.7M).

The foundation's NTEE classification (S41 — Community Development, Promotion of Philanthropy) places it alongside the following peer organizations by asset size. Note that the classification reflects IRS filing conventions rather than programmatic alignment; Warren Alpert's core work is biomedical research, not community development infrastructure.

Among peers with comparable asset bases, Pershing Square Foundation ($415M) is the most relevant comparator for grantees in health and social sector work. Both foundations favor evidence-based interventions and institutional partnerships. Warren Alpert's key differentiator is its physician-scientist board, which gives it genuine peer-review capacity for biomedical proposals — a structural advantage that Pershing Square, with its investment-oriented governance, does not replicate. For medical researchers, Warren Alpert's scientific credibility and New England institutional network represent a distinct funding channel unavailable through most community development peers.

The foundation's highest-profile 2025 activity was the Warren Alpert Foundation Prize, awarded at a Harvard Medical School symposium on October 30, 2025. The $500,000 prize — shared equally among Tomas Cihlar (Gilead Sciences), John O. Link (former Gilead, now Actio Biosciences), and Wesley Sundquist (University of Utah) — recognized the development of lenacapavir, the first HIV drug to disrupt the viral capsid. Lenacapavir received FDA approval as a twice-yearly injection and demonstrated 100% efficacy in preventing HIV in trials involving adolescent girls and young women in South Africa and Uganda, a landmark result in infectious disease medicine.

For 2026, the foundation announced the Distinguished Scholar Fellowship in gene therapy and gene editing (Children's Hospital of Philadelphia invited to nominate), alongside the neuroscience cycle with five awards expected to be announced in March 2026 (applications closed November 1, 2025). The translational immunology (non-cancer) cycle ran in 2025, with fellows announced at institutions including the J. David Gladstone Institutes, UC Berkeley, Columbia University, and the Allen Institute.

At Brown University's Warren Alpert Medical School, foundation support produced two notable 2025 research grants to active faculty, totaling approximately $1.66 million — demonstrating that the Brown relationship generates ongoing operational grants rather than only the landmark $100 million endowment gift made in 2007.

No leadership transitions have been announced in recent filings. August Schiesser has served as Executive Director continuously across multiple fiscal years, with compensation growing steadily from $293,985 to $333,741 — signaling organizational continuity.

For grants above $25,000, the LOI is your primary gatekeeping document — invest time proportional to the stakes. The LOI must include six elements: program title, program description, perceived need, goals and methodology, estimated budget with timeline, and contact information. Two to three pages is appropriate; the board reviews LOIs before deciding whether to invite full proposals, so clarity and specificity matter more than length. The quarterly submission window (January 10, April 10, July 10, October 10) is firm — submitting the day after the deadline pushes your application an entire quarter, a 3-month delay.

For medical research proposals, embed translational language throughout. The foundation's mission explicitly targets 'medical treatments or cures,' not basic science for its own sake. Proposals should answer: what disease does this address, what is the clinical endpoint, and how does this research move a patient closer to treatment? Disease areas with documented foundation investment — oncology (especially pancreatic cancer), neuroscience, immunology, HIV/virology, and gene therapy — have natural alignment. Projects in novel disease areas should map methodology to established funded themes.

For community and education proposals in New England, lead with program outcomes, not program activities. The foundation's grantees — food banks, elder services, Providence-area prep schools, Providence Promise — demonstrate track records of measurable community impact. New applicants should provide multi-year quantitative outcomes (students advanced per year, meals distributed, employment rates) and connect explicitly to the founder's philosophy of helping young people become economically independent. Proposals referencing youth education, workforce readiness, and self-sufficiency are better aligned than broad 'community health' framing.

For Distinguished Scholar Fellowship applicants, dean nomination is non-negotiable — begin institutional conversations 3–4 months before the November 1 deadline. The scientific proposal must use NIH G300 budget format, with three recommendation letters, full academic records, and a CV. The foundation expects approximately five awards per cycle and receives nominations from major research institutions nationally. Formatting requirements are precise: single-spaced, ½-inch margins, 11-point or larger font.

Do not contact the foundation for application status updates; all decisions flow through the quarterly board cycle. For large institutional grants, demonstrating prior engagement with Brown University, Harvard Medical School, or the University of Pennsylvania — or co-investigator relationships with faculty there — meaningfully strengthens credibility given the concentration of giving to those institutions.